Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.
List view / Grid view
Filter the results
Novel vaccine technologies are critical to improving the public health response to infectious disease threats that continually emerge and re-emerge, according to scientists at the NIAID...
Results from two Phase 1 clinical trials show an experimental Zika vaccine is safe and induces an immune response in healthy adults.
20 June 2016 | By Victoria White, Digital Content Producer
Inovio and GeneOne Life Science have received approval to initiate a Phase I human trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700)...